|
|
Post by otherottawaguy on Jun 21, 2016 8:21:15 GMT -5
At least Dr Markey gives them a nice send off...
GRIFFIN
SECURITIES
Member FINRA, SIPC
Keith A. Markey, Ph.D., M.B.A.
Stock Symbol NASDAQ: MNKD
Current Price $1.00
12 mos. Target Price NA
Market Cap $477.7 mln
MannKind Corp. SUSPENDING COVERAGE
Suspending Coverage : Pharmaceuticals
Terminating Coverage of MNKD Shares
We are suspending coverage of MannKind Corporation with this report as part of a reallocation of our resources. Our past reports and earnings estimates should not be used for investment decisions.
The Company is undertaking several initiatives to market Afrezza®. The plan, which was outlined over the past few months, is designed to address several key areas that contributed to the weak sales registered during the Sanofi collaboration that ended April 5th:
Physician detailing will be highly targeted to the 5,000 - 7,000 doctors who write prescriptions accounting for about 66% of the insulin market. MannKind is hiring 55 experienced reps (out of a pool of 3,000 applicants) to help doctors, notably endocrinologists, titrate the dosage to optimize the therapy and teach their patients how to use the inhalable insulin. The detailing effort, which will commence in July, will follow several presentations made at the American Diabetes Association meeting earlier this month that underscored the unique properties of Afrezza versus injectable insulin.
Efforts will soon be under way to improve patient acceptance. The Company will help patients find local doctors trained in the use of Afrezza and it is working to improve insurance coverage. These steps will complement improved packaging that will provide a variety of dosages in a titration box to facilitate dose optimization and promote broad patient acceptance. Also, the lung function test that is required prior to initiating treatment should be available in most physicians’ offices soon via a simple, handheld spirometer.
The Afrezza brand name should become better known, partly through direct-to-consumer advertising in targeted markets as well as through social media. We believe the campaign will be initiated in September quarter, since the drug will be available for the first time under the MannKind name starting in July.
The Company plans to maintain tight control over expenses. The monthly cash utilization rate should remain in the range of $10 - $12 million, despite the incremental selling costs. This means there is sufficient cash on hand following an equity financing in May to support operations into next year. A marketing partnership, which we believe is likely with evidence of growing sales in the United States, would likely provide non-dilutive financing and further acceptance of Afrezza.
|
|
|
|
Post by kbrion77 on Jun 21, 2016 8:29:35 GMT -5
Must have gotten tired of being a bull, he always had positive articles and higher price targets.
|
|
|
|
Post by peppy on Jun 21, 2016 9:05:13 GMT -5
Jefferies had a one year target of nine and a two year target of 30 on MNKD after the Sanofi contract. paraphrasing, "endocrinology acceptance channel checks"
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 21, 2016 9:53:29 GMT -5
At least he left nicely. Not for nothing but some of his questions during conference calls were head scratchers. I think most investors knew the answers to the questions he asked you had to wonder if he was a friend to MNKD. Regardless I don't think many investors held his predictions in high regards.
|
|
|
|
Post by kc on Jun 21, 2016 10:06:41 GMT -5
Better not to be followed right now. Its time to get ramped up and moving with sales. coverage hurts us today.
|
|
|
|
Post by nylefty on Jun 21, 2016 10:25:13 GMT -5
Better not to be followed right now. Its time to get ramped up and moving with sales. coverage hurts us today. That depends. Griffin coverage was positive, including the Goodbye coverage. |
|
|
|
Post by peppy on Jun 21, 2016 10:45:07 GMT -5
Better not to be followed right now. Its time to get ramped up and moving with sales. coverage hurts us today. That depends. Griffin coverage was positive, including the Goodbye coverage. when they come back .... Emmylou Harris : Together Again (1977) www.youtube.com/watch?v=RG1qTFZSiAM
Together again
My tears have stopped falling
The long lonely nights
Are now at an end
The key to my heart
You hold in your hand
And nothing else matters
We're together again
Together again
The gray skies are gone
Your back in my arms
Now where you belong
The love that we knew
Is living again
And nothing else matters
'Cause we're together again
(you know I could not help it)
|
|
|
|
Post by ilovekauai on Jun 21, 2016 11:00:02 GMT -5
Just like the Quarterly, which I absolutely abhor because we have nothing but cash burn to report, and bashers come out to jump all over the Quarterly each and every time. Next scheduled whipping comes up around mid-August. Ugh. Well, hopefully a rising script count later this year will take some of the sting out of things. Aloha.
|
|
|
|
Post by dictatorsaurus on Jun 21, 2016 11:59:33 GMT -5
Just like the Quarterly, which I absolutely abhor because we have nothing but cash burn to report, and bashers come out to jump all over the Quarterly each and every time. Next scheduled whipping comes up around mid-August. Ugh. Well, hopefully a rising script count later this year will take some of the sting out of things. Aloha. You can't blame the bashers, wall street, shorts, heck even SNY for this mess. There are infinite number of pie in the sky discussions on this board on how Afrezza "theoretically" is destined for world domination. Claiming how big pharma is shaking in it's boots, twitter cheerleading and other absurdities. Fact is, right now we are a penny stock getting hammered by the waves and the ship is taking on water, and very rapidly. I do appreciate the enthusiasm from management, but only after proving themselves and showing us that they are capable of carrying this company and showing us the ability to sell their one and ONLY product. We have a breakthrough drug that was FDA approved almost two years ago, yet we are nearing bankruptcy??? Unbelievable! I do realize my post does not necessarily add any constructive value to this discussion. But maybe it's time to accept the fact that the glass is half empty (heck it's almost completely empty) and focus on the main root cause. Personally I have no solutions. But then again, I'm not a highly paid executive who has been hired to do the job. |
|
|
|
Post by ilovekauai on Jun 21, 2016 12:14:15 GMT -5
Bankruptcy? Can't blame Sanofi? Penny stock? Glass completely empty? Ship taking on water very rapidly? Other absurdities?
Meaning no disrespect, but I sense you're not happy with your investment, if you have one. I disagree with your post in its entirety, and look to the progress made since January when yes, Sanofi dumped MNKD into the ditch like a rag doll. I guess we'll see in the next few years who is right, I look forward to the future, and any new challenges that may bring. Cheers.
|
|
|
|
Post by mnkdfann on Jun 21, 2016 12:23:52 GMT -5
A six-month old opinion of Griffin Securities: www.fool.com/investing/general/2016/01/06/this-just-in-is-this-analyst-wrong-about-the-futur.aspx"Our data feeds for Griffin Securities are currently... empty. We know the analyst has been picking stocks for a while, because the recommendations are all right up there on StreetInsider to review (and analyst's three most recent recommendations of Unilife Corporation, Ziopharm, and Intrexon are all down since Griffin picked them). We just don't have hard numbers to confirm our initial observation that Griffin's stock-picking skills seem poor." The last line needs to be updated. |
|
|
|
Post by madog365 on Jun 21, 2016 12:28:19 GMT -5
Just like the Quarterly, which I absolutely abhor because we have nothing but cash burn to report, and bashers come out to jump all over the Quarterly each and every time. Next scheduled whipping comes up around mid-August. Ugh. Well, hopefully a rising script count later this year will take some of the sting out of things. Aloha. You can't blame the bashers, wall street, shorts, heck even SNY for this mess. There are infinite number of pie in the sky discussions on this board on how Afrezza "theoretically" is destined for world domination. Claiming how big pharma is shaking in it's boots, twitter cheerleading and other absurdities. Fact is, right now we are a penny stock getting hammered by the waves and the ship is taking on water, and very rapidly. I do appreciate the enthusiasm from management, but only after proving themselves and showing us that they are capable of carrying this company and showing us the ability to sell their one and ONLY product. We have a breakthrough drug that was FDA approved almost two years ago, yet we are nearing bankruptcy??? Unbelievable! I do realize my post does not necessarily add any constructive value to this discussion. But maybe it's time to accept the fact that the glass is half empty (heck it's almost completely empty) and focus on the main root cause. Personally I have no solutions. But then again, I'm not a highly paid executive who has been hired to do the job. Personally i am very happy with how management handled the precarious position in which Sanofi left them. The last piece of the puzzle will be determined in July. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 21, 2016 12:28:52 GMT -5
I loaded up in the .90 cents area after dilution. I do agree that the quarterly with low scripts (and thats the reality of only up and running for 6 weeks) will be highlighted by everyone out there which will cause panic in share holders thus price declines. However even if we have ok scripts the cash burn might not be the focus. It could be about the scripts and the success we are having. If you have a higher cost basis I understand letting it ride for some investors but for positions bought after dilution; investors would be pretty foolish to go into the next six weeks without a strategy.
|
|
|
|
Post by nylefty on Jun 21, 2016 12:49:28 GMT -5
Bankruptcy? Can't blame Sanofi? Penny stock? Glass completely empty? Ship taking on water very rapidly? Other absurdities? Meaning no disrespect, but I sense you're not happy with your investment, if you have one. I disagree with your post in its entirety, and look to the progress made since January when yes, Sanofi dumped MNKD into the ditch like a rag doll. I guess we'll see in the next few years who is right, I look forward to the future, and any new challenges that may bring. Cheers. Well said. You have to wonder about the motives of someone who is so negative, to the point of absurdity. That sort of all-out bashing serves no one except the shorts. |
|
|
|
Post by brotherm1 on Jun 21, 2016 14:37:03 GMT -5
Their motives stick out like a sore thumb to me. Looks like we have several here now not able to properly discuss a topic, with nothing to offer, and here to bash.
|
|
